Cargando…

Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial

The aim of the study was to evaluate the overall biohumoral and metabolic effects of a 12-week add-on therapy consisting of a new nutraceutical formulation (BHC) based on berberine, hesperidin, and chromium picolinate in type 2 diabetes mellitus (T2D) patients with suboptimal glycemic compensation r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sartore, Giovanni, Ragazzi, Eugenio, Antonello, Giulia, Cosma, Chiara, Lapolla, Annunziata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308828/ https://www.ncbi.nlm.nih.gov/pubmed/34371883 http://dx.doi.org/10.3390/nu13072373

Ejemplares similares

Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study
por: Ragazzi, Eugenio, et al.
Publicado: (2023)

Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study
por: Yu, Shengsheng, et al.
Publicado: (2016)

Curcumin and Boswellia serrata Modulate the Glyco-Oxidative Status and Lipo-Oxidation in Master Athletes
por: Chilelli, Nino Cristiano, et al.
Publicado: (2016)

The Burden of Impaired Serum Albumin Antioxidant Properties and Glyco-Oxidation in Coronary Heart Disease Patients with and without Type 2 Diabetes Mellitus
por: Piarulli, Francesco, et al.
Publicado: (2022)

A role of glycation and methylation for SARS-CoV-2 infection in diabetes?
por: Sartore, Giovanni, et al.
Publicado: (2020)

Telemedicine and its acceptance by patients with type 2 diabetes mellitus at a single care center during the COVID-19 emergency: A cross-sectional observational study
por: Sartore, Giovanni, et al.
Publicado: (2023)

Long-term HbA1c variability and macro-/micro-vascular complications in type 2 diabetes mellitus: a meta-analysis update
por: Sartore, Giovanni, et al.
Publicado: (2023)

Omicron Variant of SARS-CoV-2 Virus: In Silico Evaluation of the Possible Impact on People Affected by Diabetes Mellitus
por: Bassani, Davide, et al.
Publicado: (2022)

Erratum to “Mediterranean Diet and Red Yeast Rice Supplementation for the Management of Hyperlipidemia in Statin-Intolerant Patients with or without Type 2 Diabetes”
por: Sartore, Giovanni, et al.
Publicado: (2014)

Mediterranean Diet and Red Yeast Rice Supplementation for the Management of Hyperlipidemia in Statin-Intolerant Patients with or without Type 2 Diabetes
por: Giovanni, Sartore, et al.
Publicado: (2013)

In silico evaluation of the interaction between ACE2 and SARS-CoV-2 Spike protein in a hyperglycemic environment
por: Sartore, Giovanni, et al.
Publicado: (2021)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

The Emerging Role of Telemedicine in Managing Glycemic Control and Psychobehavioral Aspects of Pregnancy Complicated by Diabetes
por: Chilelli, Nino Cristiano, et al.
Publicado: (2014)

Abscisic Acid: A Novel Nutraceutical for Glycemic Control
por: Zocchi, Elena, et al.
Publicado: (2017)

Frequency and predictors of suboptimal glycemic control in an African diabetic population
por: Kibirige, Davis, et al.
Publicado: (2017)

Low Glucose Concentrations Induce a Similar Inflammatory Response in Monocytes from Type 2 Diabetic Patients and Healthy Subjects
por: Piarulli, Francesco, et al.
Publicado: (2017)

Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DM
por: Sartore, Giovanni, et al.
Publicado: (2020)

Characteristics of Children with Type 1 Diabetes and Persistent Suboptimal Glycemic Control
por: Kim, Hyuntae, et al.
Publicado: (2012)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
por: Philip, Elizabeth, et al.
Publicado: (2013)

Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update
por: Piarulli, Francesco, et al.
Publicado: (2012)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)
por: Zenari, Luciano, et al.
Publicado: (2020)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
por: Takahashi, Hiroshi, et al.
Publicado: (2018)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
por: Hirst, Jennifer A., et al.
Publicado: (2012)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
por: Eckel, Robert H., et al.
Publicado: (2015)

Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose
por: Chen, Po-Hsun, et al.
Publicado: (2014)

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
por: Tentolouris, Nikolaos, et al.
Publicado: (2019)

In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model
por: Stellavato, Antonietta, et al.
Publicado: (2018)

Metformin in COVID-19: Is There a Role Beyond Glycemic Control?
por: Nagendra, Lakshmi, et al.
Publicado: (2023)

Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial
por: Ji, Linong, et al.
Publicado: (2013)

HbA(1c) After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes
por: Zeitler, Phil, et al.
Publicado: (2015)

Correction to: In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model
por: Stellavato, Antonietta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7i1656qg42dovnn7dmup31kbv7